Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Lymphoma | Research

MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation

Authors: Mohammad Rafiee, Fatemeh Amiri, Mohammad Hossein Mohammadi, Abbas Hajifathali

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Relapse is a frequent occurrence in autologous hematopoietic stem cell transplantation (AHSCT), and early relapse after AHSCT results in poor survival and low quality of life. Predictive marker determination for AHSCT outcomes could be helpful in the prevention of relapse through personalized medicine. Here the predictive value of circulatory microRNAs (miRs) expression for AHSCT outcomes was studied.

Methods

50 MM and lymphoma candidates for AHSCT participated in this study. Two plasma samples were obtained before AHSCT from each candidate; one before mobilization and the other after conditioning. Extracellular vesicles (EVs) were isolated by ultracentrifugation. miR-125b, miR-126, miR-150, and miR-155 expression were analyzed in both plasma and EVs using real time polymerase chain reaction analysis. Other data related to AHSCT and its outcomes were also collected. The predictive value of miRs and other factors for outcomes was assessed by multi-variant analysis.

Results

By 90 weeks follow up after AHSCT, multi-variant and ROC analysis showed miR-125b as a predictive marker for relapse, high lactate dehydrogenase (LDH), and high erythrocyte sedimentation rate (ESR). The cumulative incidence of relapse, high LDH, and high ESR increased with an increase in circulatory miR-125b expression.

Conclusion

miR-125b could be applicable in prognosis evaluation and also create a possible new targeted therapy opportunity for enhanced outcomes and survival after AHSCT.

Trial registration

The study was retrospectively registered. Ethic code No: IR.UMSHA.REC.1400.541.
Literature
1.
Vaxman I, Visram A, Kumar S, Dispenzieri A, Buadi F, Dingli D, et al. Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. Bone Marrow Transplant. 2021;56(5):1144–50.CrossRefPubMed
2.
Wudhikarn K, Johnson BK, Villasboas JC, Paludo J, Inwards DJ, Porrata LF, et al. Improvement in outcomes of autologous stem cell transplant in patients with Lymphoma Older Than 70 years: the significance of age in 2020s? Blood. 2021;138:2908.CrossRef
3.
Chen Y-B, McCarthy PL, Hahn T, Holstein SA, Ueda M, Kröger N, et al. Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. Bone Marrow Transplant. 2019;54(4):497–507.CrossRefPubMed
4.
Corre J, Montes L, Martin E, Perrot A, Caillot D, Leleu X, et al. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica. 2020;105(9):e480.CrossRefPubMedPubMedCentral
5.
Alegre A, Granda A, Martínez-Chamorro C, Díaz-Mediavilla J, Martínez R, García-Laraña J, et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica. 2002;87(6):609–14.PubMed
6.
Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. ASH Educ Program Book. 2008;2008(1):326–33.
7.
Kornacker M, Stumm J, Pott C, Dietrich S, Süssmilch S, Hensel M, et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol. 2009;20(4):722–8.CrossRefPubMed
8.
Asgarpour K, Shojaei Z, Amiri F, Ai J, Mahjoubin-Tehran M, Ghasemi F, et al. Exosomal microRNAs derived from mesenchymal stem cells: cell-to-cell messages. Cell Commun Signal. 2020;18(1):1–16.CrossRef
9.
Han B, Wang S, Zhao H. MicroRNA-21 and microRNA-155 promote the progression of Burkitt’s lymphoma by the PI3K/AKT signaling pathway. IJ Clin Exp Pathol. 2020;13(1):89.
10.
Zhan C, Wang T, You H, Si C. Different expressions of miR-125b and SOX30 in malignant lymphomas and their significance. J BUON. 2018;23(4):1179–84.PubMed
11.
Lone W, Bouska A, Sharma S, Amador C, Saumyaranjan M, Herek TA, et al. Genome-wide miRNA expression profiling of molecular subgroups of peripheral T-cell lymphoma. Clin Cancer Res. 2021;27(21):6039–53.CrossRefPubMedPubMedCentral
12.
Wu SJ, Chen J, Wu B, Wang YJ, Guo KY. MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma. J Exp Clin Cancer Res. 2018;37(1):1–10.CrossRef
13.
Amodio N, Gallo Cantafio ME, Botta C, Agosti V, Federico C, Caracciolo D, et al. Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma. Cancer. 2019;11(2):236.CrossRef
14.
Ma Y, Li C, Huang Y, Wang Y, Xia X, Zheng CJ. Exosomes released from neural progenitor cells and induced neural progenitor cells regulate neurogenesis through miR-21a. Cell Commun Signal. 2019;17:96.CrossRefPubMedPubMedCentral
15.
Rafiee M, Allahbakhshian FM, Amiri V, Hajifathali A, Gharehbaghian A, Mohammadi MH. Circulatory miR–155 correlation with platelet and neutrophil recovery after autologous hematopoietic stem cell transplantation a multivariate analysis. Int J Hematol. 2021;114(2):235–45.CrossRefPubMed
16.
Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol blood Marrow Transplant. 2008;14(8):904–12.CrossRefPubMedPubMedCentral
17.
Malard F, Harousseau J, Mohty M. Multiple myeloma treatment at relapse after autologous stem cell transplantation: a practical analysis. Cancer Treat Rev. 2017;52:41–7.CrossRefPubMed
18.
Sureda A, André M, Borchmann P, da Silva MG, Gisselbrecht C, Vassilakopoulos TP, et al. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a european expert perspective. BMC Cancer. 2020;20(1):1–14.CrossRef
19.
Jiang Y, Luan Y, Chang H, Chen G. The diagnostic and prognostic value of plasma microRNA–125b–5p in patients with multiple myeloma. OncolLett. 2018;16(3):4001–7.
20.
Gao D, Xiao Z, Li HP, Han DH, Zhang YP. The mechanism study of miR-125b in occurrence and progression of multiple myeloma. Cancer Med. 2018;7(1):134–45.CrossRefPubMed
21.
Jiang Y, Ding J, Li J, Chen G. Effects of microRNA–125b on multiple myeloma cell growth in vitro and in vivo. Oncol Rep. 2018;40(5):2864–75.PubMed
22.
Wang Y, Wei Y, Fan X, Zhang P, Wang P, Cheng S, et al. MicroRNA-125b as a tumor suppressor by targeting MMP11 in breast cancer. ThoracCancer. 2020;11(6):1613–20.
23.
Murray M, Rushworth SA, Zaitseva L, Bowles KM, MacEwan DJ. Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle. 2013;12(13):2144–53.CrossRefPubMedPubMedCentral
24.
Misso G, Zarone MR, Lombardi A, Grimaldi A, Cossu AM, Ferri C, et al. miR-125b upregulates miR-34a and sequentially activates stress adaption and cell death mechanisms in multiple myeloma. Mol Ther Nucleic Acids. 2019;16:391–406.CrossRefPubMedPubMedCentral
25.
Feng Y, Zhong M, Zeng S, Wang L, Liu P, Xiao X, et al. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics. 2019;11(1):35–51.CrossRefPubMed
26.
Yuan WX, Gui YX, Na WN, Chao J, Yang X. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. Oncol Lett. 2016;11(1):423–32.CrossRefPubMed
27.
Kim S-W, Ramasamy K, Bouamar H, Lin A-P, Jiang D, Aguiar RC. MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). PNAS. 2012;109(20):7865–70.CrossRefPubMedPubMedCentral
28.
Peng B, Theng PY, Le MT. Essential functions of miR-125b in cancer. Cell Prolif. 2021;54(2):e12913.CrossRefPubMed
29.
Li G, So AY-L, Sookram R, Wong S, Wang JK, Ouyang Y, et al. Epigenetic silencing of miR-125b is required for normal B-cell development. Blood. 2018;131(17):1920–30.CrossRefPubMedPubMedCentral
30.
Gu Y, Yuan Y-H, Xu J, Shi Q-L, Qu X-Y, Guo R, et al. High serum lactate dehydrogenase predicts an unfavorable outcome in chinese elderly patients with multiple myeloma. Oncotarget. 2017;8(29):48350.CrossRefPubMedPubMedCentral
31.
Shouval R, Teper O, Fein JA, Danylesko I, Shem Tov N, Yerushalmi R, et al. LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020;55(9):1736–43.CrossRefPubMed
32.
Dimopoulos MA, Kastritis E, Roussou M, Gkotzamanidou M, Migkou M, Gavriatopoulou M, et al. Elevated serum lactate dehydrogenase (LDH) should be included among the variables which define high risk multiple myeloma. Am Society Hematol; 2010.
33.
Huang B, Li J, Lu J, Xiao Y, Zhao Y, Huang H. Scoring system for predicting risk of relapse in patients with multiple myeloma within two years after stem cell transplantation. Am Society Hematol Washington, DC; 2017.
34.
Sorror M, Storer B, Gopal A, Holmberg L, Sandmaier B, Bensinger W, et al. Comorbidity, Lactate dehydrogenase (LDH), and Chemosensitivity are independent predictors of mortality after autologous hematopoietic cell transplantation (HCT) for patients (pts) with lymphoma. Blood. 2007;110(11):616.CrossRef
35.
William BM, Bongu NR, Bast M, Bociek RG, Bierman PJ, Vose JM, et al. The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma. Rev bras hematol hemoter. 2013;35:189–91.PubMedPubMedCentral
36.
Alexandrakis M, Passam F, Ganotakis E, Sfiridaki K, Xilouri I, Perisinakis K, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL‐6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol. 2003;25(1):41–6.CrossRefPubMed
37.
Bien E, Balcerska A. Serum Soluble Interleukin-2 receptor, Beta2‐Microglobulin, Lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin’s lymphoma. Scand J immunol. 2009;70(5):490–500.CrossRefPubMed
38.
Friedman S, Henry-Amar M, Cosset JM, Carde P, Hayat M, Dupouy N, et al. Therapeutic implications and sites of relapse predicted by elevated posttherapy erythrocyte sedimentation rate in early stage Hodgkin disease. Am J hematol. 1991;37(4):253–7.CrossRefPubMed
39.
Henry-Amar M, Friedman S, Hayat M, Somers R, Meerwaldt JH, Carde P, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. Ann Inter Med. 1991;114(5):361–5.CrossRef
40.
Zheng Z, Qu J-Q, Yi H-M, Ye X, Huang W, Xiao T, et al. MiR-125b regulates proliferation and apoptosis of nasopharyngeal carcinoma by targeting A20/NF-κB signaling pathway. Cell Death Disease. 2017;8(6):e2855–e.CrossRefPubMedPubMedCentral
Metadata
Title
MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation
Authors
Mohammad Rafiee
Fatemeh Amiri
Mohammad Hossein Mohammadi
Abbas Hajifathali
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10665-0

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Analysis of cells of epithelial, connective tissue and immune differentiation in HPV-positive-, HPV-negative oropharyngeal carcinoma and normal oropharyngeal tissue by immunofluorescence multiplex image cytometry: a preliminary report

Research

Understanding the contribution of lifestyle in breast cancer risk prediction: a systematic review of models applicable to Europe

Research

Plasma exosome-derived connexin43 as a promising biomarker for melanoma patients

Research

Quantitative CT parameters combined with preoperative systemic inflammatory markers for differentiating risk subgroups of thymic epithelial tumors

Research

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases

Research

Alternating electric fields can improve chemotherapy treatment efficacy in blood cancer cell U937 (non-adherent cells)

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits